DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,670.229 B2 Hitchcock Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,670.229 B2 Hitchcock Et Al USOO9670229B2 (12) United States Patent (10) Patent No.: US 9,670.229 B2 Hitchcock et al. (45) Date of Patent: Jun. 6, 2017 (54) 5-HT3 RECEPTOR ANTAGONISTS USPC ................ 514/230.5, 299; 544/105:546/121 See application file for complete search history. (71) Applicant: Takeda Pharmaceutical Company Limited, San Diego, CA (US) (56) References Cited (72) Inventors: Stephen Hitchcock, San Diego, CA U.S. PATENT DOCUMENTS (US); Holger Monenschein, San Diego, CA (US); Holly Reichard, San Diego, 266 A 133 Ronal CA (US): Huikai Sun, San Diego, CA wW - onalscnet al. tSEN's,s s 5. s A 4,910,4,886,808. 193 A 12/19893, 1990 KingBuchheit et al. et al. (US); Todd Macklin, San Diego, CA 5,034,398 A 7/1991 King et al. (US); Maria Hopkins, San Diego, CA 5,298,510 A 3/1994 Tyers (US) 5,344,831 A 9/1994 Satoh et al. 9.012,447 B2 * 4/2015 Hitchcock ............ CO7D 498.08 (73) Assignee: Takeda Pharmaceutical Company 9,346,829 B2 * 5/2016 Hitchcock ............ coisi's Limited, Osaka (JP) 2004/0038958 A1 2/2004 Rundfeldt et al. 2005/0234095 A1 10, 2005 Xie et al. (*) Notice: Subject to any disclaimer, the term of this 2007,0191313 A1 8, 2007 Beard et al. patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 15/150,013 EP O200444 5, 1986 (22) Filed: May 9, 2016 EP O469449 2, 1992 EP O491664 6, 1992 (65) Prior Publication Data (Continued) US 2016/O251373 A1 Sep. 1, 2016 OTHER PUBLICATIONS O O Naghdi et al. “The effect of intrahippocampal injections of ritanserin Related U.S. Application Data (5HT2A/2C antagonist) and granisetron (5HT3 antagonist) on (62) Division of application No. 14/645,639, filed on Mar. learning as assessed in the spatial version of the water maze' 12, 2015, now Pat. No. 9,346,829, which is a division Behavioural Brain Research 157 (2005) p. 205-210. of application No. 13/943,634, filed on Jul. 16, 2013, (Continued) now Pat. No. 9,012,447. Primary Examiner — Kahsay Habte (60) Provisional application No. 61/708,521, filed on Oct. (74) Attorney, Agent, or Firm — Matthew J. Russo; David 1, 2012, provisional application No. 61/672,709, filed M. Stemerick on Jul. 17, 2012. (51) Int. Cl. (57) ABSTRACT C07D 519/00 (2006.01) The present invention provides 5-HT3 receptor antagonists CO7D 49.8/08 (2006.01) of Formula (I): CO7D 47L/04 (2006.01) CO7D 451/12 (2006.01) CO7D 22L/22 (2006.01) (I) A6 IK3I/I9 (2006.01) . A6 IK3I/5386 (2006.01) O Z CD7C 53/40 (2006.01) CO7D 453/02 (2006.01) -X4 CO7D 47/08 (2006.01) n \ C07C 53/18 (2006.01) X2, 2 /* (52) U.S. Cl. nx, N CPC ............ C07D 498/08 (2013.01); A61K 31/19 R4 (2013.01); A61 K3I/5386 (2013.01); C07C 53/18 (2013.01); C07C 53/40 (2013.01); C07D 221/22 (2013.01); C07D 451/12 (2013.01); which are useful for the treatment of diseases treatable by C07D 453/02 (2013.01); C07D 471/04 inhibition of 5-HT3 receptor such as emesis, pain, drug (2013.01); C07D 471/08 (2013.01); C07D addiction, neurodegenerative and psychiatric disorders, and 519/00 (2013.01) GI disorders. Also provided are pharmaceutical composi (58) Field of Classification Search tions containing Such compounds and processes for prepar CPC. C07D 51.9/00; C07D 498/08; C07D 471/04; ing Such compounds. C07D 451/12: C07D 221/22: A61 K 31/19; A61K 31/5386 11 Claims, No Drawings US 9,670.229 B2 Page 2 (56) References Cited U.S. PATENT DOCUMENTS 2011/0319407 A1 12/2011 Xie et al. FOREIGN PATENT DOCUMENTS EP O558923 9, 1993 EP O708105 4f1996 EP 1156.045 11 2001 EP 1243268 9, 2002 WO WO95/27.490 10, 1995 WO WOf O3,035.625 5, 2003 WO WO, 2004/OO6920 1, 2004 WO WO, 2004/O290SO 4/2004 WO WO, 2005/092890 10/2005 WO WO, 2006/077365 T 2006 WO WO, 2007/038367 4/2007 WO WO, 2007/095561 8, 2007 WO WO, 2008/048.981 4/2008 WO WO, 2008/097930 8, 2008 WO WO, 2008/100867 8, 2008 WO WO, 2009/023623 2, 2009 WO WO, 2011/126821 10, 2011 WO WO, 2011, 153553 12, 2011 OTHER PUBLICATIONS Javadi-Paydar et al. “Involvement of nitric oxide in granisetron improving effect on Scopolamine-induced memory impairment in mice” Brain Research 1429 (2 0 1 2) p. 6 1-7 1. * cited by examiner US 9,670,229 B2 1. 2 5-HT3 RECEPTOR ANTAGONSTS son and Lummis 2007 Exp Opin Ther Targets, 11, 527-540). In addition, 5-HT3 receptors are expressed in the GI tract and hence may play a role in GI disorders such as dyspepsia, RELATED APPLICATIONS gastroesophagal reflux disease and irritable bowel syndrome (see Graeff 1997 Psychiatr Clin North Am 20, 723: Thomp This application claims the benefit of U.S. Provisional son and Lummis 2007 Exp Opin Ther Targets, 11, 527-540: Application No. 61/672,709, filed Jul. 17, 2012, and U.S. Barnes et al. 2009 Neuropharmacology 56, 273). Expression Provisional Application No. 61/708,521, filed Oct. 1, 2012, of the 5-HT3A subsunit has also been discovered extraneu ronally in immune cells Such as monocyes, chondrocytes, which are herein incorporated by reference. T-cells, synovial tissue and platelets (Fiebich et al., 2004 10 Scan J Rheumatol Suppl, 9-11, Stratz et al., 2008 Thromb FIELD OF INVENTION Haemost 99, 784) and of 5-HT3A, C-E within the lamina propia in the epithelium of the gut mucose (Kapeller et al., The present invention provides compounds that are J Comp Neuro., 2008: 509: 356-371) thus suggesting they 5-HT3 receptor antagonists and are therefore useful for the may be involved in immunological and inflammatory dis treatment of diseases treatable by inhibition of the 5-HT3 eases like atherosclerosis, tendomyopathies and fibromyal 15 1a. receptor Such as emesis, pain, drug addiction, neurodegen 9. The 5-HT3 antagonists currently on the market are erative and psychiatric disorders, and GI disorders. Also approved only for the treatment of emesis or irritable bowel provided are pharmaceutical compositions containing Such syndrome. It is desirable to discover 5-HT3 antagonists that compounds and processes for preparing Such compounds. can be used to treat other diseases amenable to alleviation by 5-HT3 receptors such as Schizophrenia and cognitive disor BACKGROUND der associated with Schizophrenia. The present invention can fulfill this and related needs. It is desirable to discover Serotonin type 3 (5-HT3) receptors are part of the sero 5-HT3 antagonists that have desirable pharmacokinetic and tonergic system. Unlike other receptors of this system, pharmacodynamic properties, such as selectivity over nico which are all G-protein coupled receptors, the 5-HT3 recep tinic-C7 receptors. tors are ligand-gated ion channels and belongs to the Super 25 Certain antagonists the 5-HT3 receptor are described in family of Cys-loop receptors that include nicotinic acetyl U.S. Pat. Nos. 4,789,763; 4,803, 199: 4,886,808: 4,910, 193; choline, Y-aminobutyric acid (GABA)A and glycine 5,334,831; EP O 469 449; and EP O 491 664. Certain receptors and a Zn-2 activated cation channel (see Davies et inhibitors of TGF-B are described in EP 1 156 045 and al., 2003, J. Biol. Chem., 278, 712-717: Connolly et al., certain treatment of nephritis is described in EP1 243 268. 2004, Biochem Soc Trans 32, 529-534). The 5-HT, receptors 30 are made up of 5 subunits arranged around a central ion Certain antagonists of 5-HT4 are described in EP 0708 105. conducting pore, which is permeable to sodium, potassium, Certain ligands of nicotinic-C7 receptors are described in and calcium ions (see Boess et al., 1995, J. Neurochem. 64. WO 2007/038367. Certain P2X7 antagonists are disclosed 1401-1405; Connolly et al., 2004, Biochem Soc Trans 32, in WO 2009/O23623. 529-534). Binding of serotonin to the 5-HT receptors opens the channel, which, in turn, leads to an excitatory response 35 SUMMARY in neurons. Functional data reported for 5-HT3 receptors refer to 5-HT3A or 5-HT3AB receptors since the properties In a first aspect, this invention is directed to a compound of these receptor subtypes have been most extensively of Formula (I): studies to date. 5-HT3 receptors are known to be expressed in the central 40 nervous system in regions involving vomiting reflex, pro (I) cessing of pain, cognition and anxiety control and play a role R in the pathogenesis of diseases such as emesis, migraine, drug addiction, and neurodegenerative and psychiatric dis “N 4 orders such as anxiety and depression (see Hewlett et al., 2003.J. Clin. Psychiatry 64, 1025-1030; Kelley et al., 2003a, 45 X4 Eur J Pharmacol., 461, 19-25; Haus et al., 2000 Scand J Rheumatol Suppl 113, 55-58; and Faris et al., 2006 J affect X2 2 N^ Disorder 92, 79-90), eating disorders (Hammer et al., 1990 Am J Physiol 259, R627-R636, and Jiang & Gietzen 1994 R4 Pharmacol Biochem Behav 47, 59-63), schizophrenia (see 50 Hermann et al. 1996 Biochem Biophy's Res Commun 225, 957-960; Sirota et al., 2000 Am J Psychiatry 157, 287-289; wherein: Adler et al., 2005 Am J Psychiatry 162, 386-388: Koike et Z is O or NR where R is hydrogen or C. alkyl: al., Levkovitz et al., 2005 Schizophr Res 76, 67-72), cogni R is a ring of the formula (a)-(h) below: tive dysfunction associated with schizophrenia (see Zhanget 55 al., 2006 Schizophr Res 88, 102-110; Akhondzadeh et al., 2009 Schizophr Res 107, 206-212), congnitive dysfuntion (a) associated with Parkinson's disease, Huntington’s Chorea, presenile dementias and Alzheimer's disease (see Costall and Naylor 2004 CNS Neurol Disord 3, 27-37) substance abuse and addiction (see Johnson et al., 2002 Psycho 60 pharmacology (Berl) 160, 408-413: Johnson, 2004 CNS Drugs 18, 1105-1118; Dawes et al., 2005 Addict Behav 30, 1630-1637, Johnson 2006 Drug Alcohol Depend 84, 256 263), autish spectrum disorders (see Anderson et al Neuro genetics 10, 209-216) and pain (see Kayser et al., 2007 Pain 65 130, 235; Glaum et al., 1998 Neurosci Lett 95, 313-317; Schworer & Ramadori 1993 Clin Investig 71, 659; Thomp US 9,670,229 B2 3 4 -continued all of X-X are CRs or one of X-X is N and the others are (b) CRs: each Rs is independently hydrogen, C.
Load more

Recommended publications
  • Présentation HJ
    Conflits d’intérêts Astra-Zeneca, Janssen, Abacus international, Laboratoire ETAP, Institut Pasteur. Dr Hervé JAVELOT Pharmacien PH Etablissement Public de Santé Alsace Nord Service Pharmacie 141 avenue de Strasbourg 67 170 BRUMATH Tél. : 03 88 64 61 70 Fax : 03 88 64 61 58 Mail : [email protected] Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Hervé JAVELOT Etablissement Public de Santé Alsace Nord Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Traitements des troubles anxio-dépressifs. Les perspectives. ◦ L’axe GABAergique…éternellement prometteur ? ◦ L’incontournable théorie « monoaminergique »… ◦ Des théories alternatives à suivre … Traitements des troubles anxio-dépressifs. Contexte : ◦ XXI ème siècle : Le « siècle de la dépression » s’installe ? (Hardeveld et al., 2010) L’« ère de l’angoisse » s’affirme ? (Auden, 1947) ◦ Prévalence au cours de la vie : 16 à 17% pour la dépression, 17 à 18% pour les troubles anxieux Co-morbidité des 2 troubles dans 20 à 40% des cas (Antony, 2011 ; Depping et al., 2010 ; Hardeveld et al., 2010 ; Huppert, 2009) Auden WH (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-91. Antony MM. Recent advances in the treatment of anxiety disorders. Canadian Psychology 2011;52(1), 10-19. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. Huppert JD. Anxiety disorders and depression comorbidity.
    [Show full text]
  • A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling
    biomolecules Review Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling Christopher L. Cioffi Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA; christopher.cioffi@acphs.edu; Tel.: +1-518-694-7224 Abstract: Among the myriad of cellular and molecular processes identified as contributing to patho- logical pain, disinhibition of spinal cord nociceptive signaling to higher cortical centers plays a critical role. Importantly, evidence suggests that impaired glycinergic neurotransmission develops in the dorsal horn of the spinal cord in inflammatory and neuropathic pain models and is a key maladaptive mechanism causing mechanical hyperalgesia and allodynia. Thus, it has been hypothesized that pharmacological agents capable of augmenting glycinergic tone within the dorsal horn may be able to blunt or block aberrant nociceptor signaling to the brain and serve as a novel class of analgesics for various pathological pain states. Indeed, drugs that enhance dysfunctional glycinergic transmission, and in particular inhibitors of the glycine transporters (GlyT1 and GlyT2), are generating widespread + − interest as a potential class of novel analgesics. The GlyTs are Na /Cl -dependent transporters of the solute carrier 6 (SLC6) family and it has been proposed that the inhibition of them presents a Citation: Cioffi, C.L. Inhibition of possible mechanism
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse
    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]
  • WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: Unit L, Baltimore, Maryland 21209 (US). WEINBER¬ A61K 31/535 (2006.01) GER, Daniel; 3116 Davenport St. NW, Washington, Dis trict of Columbia 20008-2244 (US). (21) International Application Number: PCT/US2016/015832 (74) Agent: KELLY, Bryte; King & Spalding LLP, 1185 Av enue of the Americas, New York, New York 10036 (US). (22) International Filing Date: 29 January 2016 (29.01 .2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/109,954 30 January 2015 (30.01.2015) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: LIEBER INSTITUTE FOR BRAIN DE¬ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, VELOPMENT [US/US]; 855 North Wolfe Street, Suite PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 300, 3rd Floor, Baltimore, Maryland 21205 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Impact of D-Cycloserine and Sarcosine on in Vivo Frontal Neural
    Yao et al. BMC Psychiatry (2019) 19:314 https://doi.org/10.1186/s12888-019-2306-1 RESEARCH ARTICLE Open Access The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model Lulu Yao1, Zongliang Wang1, Di Deng1, Rongzhen Yan1, Jun Ju1 and Qiang Zhou1,2* Abstract Background: N-methyl-D-aspartate receptor (NMDAR) hypofunction has been proposed to underlie the pathogenesis of schizophrenia. Specifically, reduced function of NMDARs leads to altered balance between excitation and inhibition which further drives neural network malfunctions. Clinical studies suggested that NMDAR modulators (glycine, D-serine, D-cycloserine and glycine transporter inhibitors) may be beneficial in treating schizophrenia patients. Preclinical evidence also suggested that these NMDAR modulators may enhance synaptic NMDAR function and synaptic plasticity in brain slices. However, an important issue that has not been addressed is whether these NMDAR modulators modulate neural activity/spiking in vivo. Methods: By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice. Results: In vivo neural activity is significantly higher in the schizophrenia-like model mice, compared to control mice. D-cycloserine and sarcosine showed no significant effect on neural activity in the schizophrenia-like model mice. Glycine induced a large reduction in movement in home cage and reduced in vivo brain activity in control mice which prevented further analysis of its effect in schizophrenia-like model mice. Conclusions: We conclude that there is no significant impact of the tested NMDAR modulators on neural spiking in the schizophrenia-like model mice.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]